Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib

Abstract

Pulmonary Sarcomatoid Carcinoma (PSC) is a rare and highly malignant subtype of Non Small Cell Lung Cancer (NSCLC). In contrast to other types of lung cancers, recent retrospective studies demonstrated that PSC always shows frequent genetic mutations, high TMB and high PD L1 expression which indicates these patients might derive survival benefits from immune checkpoint inhibitors